New treatments

This page will list articles and news about new cancer treatments approved in Canada.

AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer (December 2019)

Health Canada Approves XTANDI® (enzalutamide) – the First and Only Oral Treatment for Men with Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer (January 2019)

AGRISSO received a positive final recommendationfor listing from pCODR supporting the significant clinical benefits of TAGRISSO (osimertinib) for the first-line (1L) treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth receptor (EGFR) mutations (exon 19 deletions or exon 21 [L858R]) (January 2019)

Novartis receives Health Canada approval for the combination therapy of Tafinlar® (dabrafenib) plus Mekinist® (trametinib) for adjuvant treatment of patients with BRAF V600 mutation melanoma(i) (November 2018)

Health Canada approves PERJETA® (pertuzumab) for the treatment of HER2-positive early breast cancer after surgery (September 2018)

Health Canada Approves Tagrisso® (osimertinib) as First-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer (July 2018)

Only Immuno-Oncology Combination Therapy Approved by Health Canada as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma (July 2018)

Health Canada Approves GAZYVA® for Previously Untreated Advanced Follicular Lymphoma (July 2018)

Health Canada Approves ERLEADA™* (apalutamide tablets), the First Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer (July 2018)

ALECENSARO® (alectinib) approved by Health Canada for first-line treatment of ALK-positive lung cancer (June 2018)

Lynparza® (olaparib) Receives New Indication for BRCA-Mutated Metastatic Breast Cancer (May 2018)

First and Only Immuno-Oncology Treatment, Imfinzi® (durvalumab), for Stage III, Unresectable Non-Small Cell Lung Cancer Now Approved in Canada (May 2018)

Lynparza® (olaparib) tablets receive approval as maintenance therapy treatment for ovarian cancer regardless of BRCA status (May 2018)

Health Canada approves KISQALI™ for the treatment of HR-positive and HER2-negative metastatic breast cancer in postmenopausal women in combination with letrozole as an initial endocrine-based therapy (May 2018)

Health Canada approves TECENTRIQ® (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer (April 2018)

Health Canada Approves RITUXAN® Subcutaneous Formulation for Canadians with Chronic Lymphocytic Leukemia (March 2018)

Taiho Pharma Canada, Inc. announces Health Canada approval of LONSURF® (trifluridine and tipiracil tablets) for metastatic colorectal cancer (March 2018)